ライフサイエンスコーパス: octa-

1 including penta (28, 47, 99, 100, 153, 154), octa (183, 196, 197, 203), and decaBDEs (206-209).

2 ischemia was less than that identified with OCTA (2.3+/-3.6 clock hours vs 5.1+/-4.2 clock hours, P

3 Nonperfusion as quantified on OCTA (3 x 3 mm) correlated with UWF-FA parameters and bo

4 The macular OCTA (3x3mm) scan was performed and the computer algorit

5 most of these patients had CNV visible on SS-OCTA (71.4%; 10 of 14 eyes).

6 tapeptide and become almost the same for the octa- and decapeptide.

7 All octa- and hexasaccharide fractions tested were unable to

8 Analysis of the octa- and nona-BDE profiles suggested photolysis and pyr

9 e, up to 320 and 4350 mug/kg lipid weight of octa- and nonachlorinated CTTs were detected in four liv

10 ta- and heptameric assemblies; in the larger octa- and nonameric assemblies, ring-opened conformers w

11 nificant potential bias along the orthogonal octa- and tetra-heme chains, suggesting that under aqueo

12 Total consumption of penta-, octa-, and decaBDE from 1970 to 2020 in products conside

13 and 200-2000 g.capita(-1).y(-1) for penta-, octa-, and decaBDE, respectively, over the time span.

14 OCTA (AngioVue, Optovue) was used before surgery and at

15 tudy, participants underwent spectral-domain OCTA (AngioVue; Optovue, Inc, Fremont, CA), clinical exa

16 frared reflectance, spectral-domain OCT, and OCTA (Carl Zeiss Meditec), were performed.

17 ovue, Inc, Fremont, CA) and Cirrus/AngioPlex OCTA (Carl Zeiss Meditec, Inc, Dublin, CA) systems.

18 lion cell/inner plexiform layer [GCIPL]) and OCTA (custom: peripapillary vessel area density [pVAD],

19 ted in mice by O-SP-HSA or synthetic tetra-, octa-, dodeca-, and hexadecasaccharide fragments, was me

20 3 and 10 kDa) as models of protected tetra-, octa-, dodeca-, hexadeca-, and eicosa-nucleotides was me

21 etinal vascular diseases were considered the OCTA "experts" group.

22 - and dicyclic undecamers was used to design octa-, hepta-, and hexamers with high affinity and selec

23 conduct microscope-integrated, swept-source OCTA (MIOCTA) in children with retinal vascular disease.

24 Octa-, nona- and decanucleotide libraries were compared.

25 Complete libraries of octa-, nona- and decanucleotides were used as substrates

26 ligands resulted in prediction matrices for octa-, nona-, and decamers.

27 ed focal dark regions without flow signal on OCTA (nonperfusion).

28 significantly less likely to be detected on OCTA (odds ratio [OR]: 4.6; 95% confidence interval [CI]

29 Best Corrected Visual Acuity) recording, and OCTA (Optical Coherence Tomography Angiography) of the m

30 tinct phylogenetically from KSbeta of hexa-, octa-, or decaketide PKSs, and a dedicated phosphopantet

31 ompared with 67% sensitivity for the en face OCTA (P < 0.001).

32 x97, automatic real-time tracking: 9) and SS-OCTA (PLEX Elite 9000, Carl Zeiss Meditec, 500x500 angio

33 onsecutive patients with BVMD imaged with SS-OCTA (PLEX Elite 9000, Carl-Zeiss Meditec Inc) at the Un

34 and glaucomatous eyes were acquired with SS-OCTA (PLEX Elite 9000, ZEISS).

35 ir 20s through their 80s were imaged with SS-OCTA (PLEX Elite 9000; Carl Zeiss Meditec, Dublin, Calif

36 multimodal imaging, including SS-OCT with SS-OCTA (PLEX Elite 9000; Carl-Zeiss Meditec Inc., Dublin,

37 A projection-resolved OCTA (PR-OCTA) algorithm was used to remove flow project

38 = .006), and limbal conjunctival ischemia on OCTA (r = 0.76, P = .001).

39 All eyes underwent OCTA (RTVue-XR Avanti; Optovue, Inc, Fremont, CA).

40 filter (NDF) was attached to spectral-domain OCTA (SD-OCTA) and swept-source OCTA (SS-OCTA).

41 Swept-source OCTA (SS-OCTA) images of healthy and glaucomatous eyes.

42 ctral-domain OCTA (SD-OCTA) and swept-source OCTA (SS-OCTA).

43 on frequency of all nucleotide combinations (octa- to decanucleotides), and the combined ability of p

44 ol) molecules, at 16 muM and above, creating octa- to decasaccharides plus smaller products.